NASDAQ:SPPI

Spectrum Pharmaceuticals Competitors

$2.91
+0.02 (+0.69 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.84
Now: $2.91
$2.96
50-Day Range
$2.89
MA: $3.27
$3.91
52-Week Range
$2.60
Now: $2.91
$5.24
Volume2.85 million shs
Average Volume2.59 million shs
Market Capitalization$447.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51

Competitors

Spectrum Pharmaceuticals (NASDAQ:SPPI) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying SPPI stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Spectrum Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Volatility & Risk

Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 5.0% of Spectrum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amgen and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Spectrum PharmaceuticalsN/A-98.90%-69.77%

Analyst Recommendations

This is a breakdown of recent recommendations for Amgen and Spectrum Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen091402.61
Spectrum Pharmaceuticals01302.75

Amgen presently has a consensus price target of $261.1429, suggesting a potential upside of 0.77%. Spectrum Pharmaceuticals has a consensus price target of $9.75, suggesting a potential upside of 235.05%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Spectrum Pharmaceuticals is more favorable than Amgen.

Earnings and Valuation

This table compares Amgen and Spectrum Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.39$7.84 billion$14.8217.49
Spectrum Pharmaceuticals$109.33 million4.09$-112,690,000.00($1.14)-2.55

Amgen has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Spectrum Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Spectrum Pharmaceuticals (NASDAQ:SPPI) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

Spectrum Pharmaceuticals has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Insider and Institutional Ownership

63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spectrum Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spectrum PharmaceuticalsN/A-98.90%-69.77%
Gilead Sciences5.48%37.77%12.76%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Spectrum Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spectrum Pharmaceuticals01302.75
Gilead Sciences191302.52

Spectrum Pharmaceuticals currently has a consensus target price of $9.75, suggesting a potential upside of 235.05%. Gilead Sciences has a consensus target price of $97.68, suggesting a potential upside of 47.15%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Spectrum Pharmaceuticals is more favorable than Gilead Sciences.

Earnings & Valuation

This table compares Spectrum Pharmaceuticals and Gilead Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectrum Pharmaceuticals$109.33 million4.09$-112,690,000.00($1.14)-2.55
Gilead Sciences$22.45 billion3.72$5.39 billion$6.1410.81

Gilead Sciences has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Spectrum Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Spectrum Pharmaceuticals (NASDAQ:SPPI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

Spectrum Pharmaceuticals has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spectrum Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spectrum PharmaceuticalsN/A-98.90%-69.77%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Spectrum Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spectrum Pharmaceuticals01302.75
Vertex Pharmaceuticals042112.88

Spectrum Pharmaceuticals currently has a consensus target price of $9.75, suggesting a potential upside of 235.05%. Vertex Pharmaceuticals has a consensus target price of $293.2083, suggesting a potential upside of 33.18%. Given Spectrum Pharmaceuticals' higher possible upside, analysts clearly believe Spectrum Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Earnings & Valuation

This table compares Spectrum Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectrum Pharmaceuticals$109.33 million4.09$-112,690,000.00($1.14)-2.55
Vertex Pharmaceuticals$4.16 billion13.69$1.18 billion$4.2951.32

Vertex Pharmaceuticals has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Spectrum Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Regeneron Pharmaceuticals and Spectrum Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Spectrum Pharmaceuticals01302.75

Regeneron Pharmaceuticals currently has a consensus price target of $644.1739, indicating a potential upside of 27.71%. Spectrum Pharmaceuticals has a consensus price target of $9.75, indicating a potential upside of 235.05%. Given Spectrum Pharmaceuticals' higher possible upside, analysts plainly believe Spectrum Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Spectrum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Spectrum Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.87$2.12 billion$21.4723.49
Spectrum Pharmaceuticals$109.33 million4.09$-112,690,000.00($1.14)-2.55

Regeneron Pharmaceuticals has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Spectrum PharmaceuticalsN/A-98.90%-69.77%

Summary

Regeneron Pharmaceuticals beats Spectrum Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Spectrum Pharmaceuticals (NASDAQ:SPPI) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Profitability

This table compares Spectrum Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spectrum PharmaceuticalsN/A-98.90%-69.77%
Biogen35.63%51.00%23.54%

Valuation & Earnings

This table compares Spectrum Pharmaceuticals and Biogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectrum Pharmaceuticals$109.33 million4.09$-112,690,000.00($1.14)-2.55
Biogen$14.38 billion2.89$5.89 billion$33.578.14

Biogen has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Spectrum Pharmaceuticals has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

63.6% of Spectrum Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Spectrum Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spectrum Pharmaceuticals01302.75
Biogen5141202.23

Spectrum Pharmaceuticals presently has a consensus target price of $9.75, indicating a potential upside of 235.05%. Biogen has a consensus target price of $303.3103, indicating a potential upside of 11.02%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Spectrum Pharmaceuticals is more favorable than Biogen.

Summary

Biogen beats Spectrum Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Alexion Pharmaceuticals and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Spectrum PharmaceuticalsN/A-98.90%-69.77%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and Spectrum Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Spectrum Pharmaceuticals01302.75

Alexion Pharmaceuticals currently has a consensus price target of $153.4286, indicating a potential downside of 7.87%. Spectrum Pharmaceuticals has a consensus price target of $9.75, indicating a potential upside of 235.05%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Spectrum Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Spectrum Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.37$2.40 billion$9.7417.10
Spectrum Pharmaceuticals$109.33 million4.09$-112,690,000.00($1.14)-2.55

Alexion Pharmaceuticals has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Spectrum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Spectrum Pharmaceuticals on 11 of the 15 factors compared between the two stocks.


Spectrum Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$259.14+1.2%$149.21 billion$23.36 billion20.90Upcoming Earnings
Analyst Report
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.38+0.6%$83.58 billion$22.45 billion68.43Analyst Report
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.16+0.4%$56.98 billion$4.16 billion27.80Analyst Report
Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$504.42+0.9%$54.04 billion$7.86 billion18.44Analyst Report
Biogen logo
BIIB
Biogen
1.9$273.20+1.5%$41.62 billion$14.38 billion9.04Upcoming Earnings
Analyst Report
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$166.54+0.6%$36.79 billion$4.99 billion38.91
Seagen logo
SGEN
Seagen
1.7$144.76+0.5%$26.25 billion$916.71 million56.99
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.62+1.5%$21.24 billion$876.29 million-56.84Analyst Upgrade
Incyte logo
INCY
Incyte
1.6$84.57+2.2%$18.59 billion$2.16 billion-53.87
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.03+1.0%$15.96 billion$219.75 million-17.37Analyst Report
Gap Up
Novavax logo
NVAX
Novavax
1.4$208.15+6.4%$15.37 billion$18.66 million-39.88Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.45+0.2%$14.45 billion$1.70 billion18.18Analyst Report
Insider Selling
Repligen logo
RGEN
Repligen
1.5$211.99+0.0%$11.61 billion$270.24 million258.52Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$207.58+1.8%$9.25 billion$1.45 billion19.64
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.16+1.4%$9.09 billion$788.10 million103.40Analyst Report
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$24.51+3.1%$7.67 billion$967.78 million51.06Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.83+1.6%$6.71 billion$195.99 million292.69
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.16+3.0%$5.80 billion$1.12 billion85.75Analyst Report
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.76+2.1%$4.03 billion$806.43 million-9.46Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.62+3.4%$3.52 billion$1.11 billion21.10High Trading Volume
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.16+0.5%$3.21 billion$1.17 billion-43.83Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.29+1.1%$3.16 billion$36.13 million-67.60
OPKO Health logo
OPK
OPKO Health
1.9$4.13+1.7%$2.77 billion$901.90 million-22.94
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.79+1.2%$2.59 billion$182.24 million-8.51Analyst Upgrade
Insider Selling
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.76+0.5%$2.44 billion$120.28 million-148.24Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$26.61+2.3%$2.05 billion$638.60 million-10.23Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$126.33+4.1%$2.02 billionN/A-11.41News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.11+3.6%$1.97 billion$48.83 million-14.62
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.66+0.5%$1.72 billion$428.41 million15.45Analyst Upgrade
News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.53+1.9%$1.66 billion$102.43 million-19.22
Codexis logo
CDXS
Codexis
1.3$22.89+1.4%$1.47 billion$68.46 million-65.40Analyst Report
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.32+1.2%$1.46 billion$82.27 million-17.85
Innoviva logo
INVA
Innoviva
1.4$11.98+0.8%$1.21 billion$261.02 million6.11News Coverage
MannKind logo
MNKD
MannKind
1.4$4.23+1.7%$1.05 billion$63.04 million-20.14Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.94+21.8%$1.01 billion$35.22 million-6.53
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.67+2.0%$937.69 million$3.57 million-10.61
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.55+0.7%$908.31 million$227.19 million45.97Analyst Downgrade
Curis logo
CRIS
Curis
1.3$9.82+5.0%$898.72 million$10 million-11.98
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.34+0.2%$884.22 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88+0.8%$704.45 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80+2.9%$689.77 million$252 million-2.13
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17+0.9%$682.20 million$150,000.00-4.53
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55+2.0%$603.93 million$59.29 million-23.67Increase in Short Interest
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.67+1.9%$592.69 million$143.01 million-1.08
Agenus logo
AGEN
Agenus
1.6$2.68+4.1%$547.53 million$150.05 million-2.45
Verastem logo
VSTM
Verastem
1.3$2.71+0.4%$465.22 million$17.46 million-1.92
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96+4.1%$446.17 million$22.27 million-3.90Analyst Revision
Geron logo
GERN
Geron
1.4$1.40+0.0%$445.94 million$460,000.00-4.00Decrease in Short Interest
XOMA logo
XOMA
XOMA
1.5$35.44+1.6%$398.98 million$18.37 million-31.93Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$4.01+1.0%$380.58 million$36.63 million-4.72Analyst Report
Gap Up
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.